MEI Pharma (MEIP) Receiving Somewhat Favorable Media Coverage, Report Shows

News coverage about MEI Pharma (NASDAQ:MEIP) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a news impact score of 0.24 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.7819861095766 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

A number of brokerages have commented on MEIP. Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. set a $7.00 price objective on shares of MEI Pharma and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Finally, Cann restated a “buy” rating and set a $6.50 price objective on shares of MEI Pharma in a research report on Monday, June 26th.

Shares of MEI Pharma (NASDAQ:MEIP) traded down 2.17% during trading on Wednesday, reaching $2.70. 109,659 shares of the company’s stock were exchanged. The stock has a market capitalization of $99.73 million, a PE ratio of 38.57 and a beta of 1.65. MEI Pharma has a 52 week low of $1.34 and a 52 week high of $3.26. The company’s 50-day moving average is $2.76 and its 200 day moving average is $2.13.

MEI Pharma (NASDAQ:MEIP) last announced its quarterly earnings results on Tuesday, September 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. MEI Pharma had a net margin of 11.48% and a return on equity of 5.26%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.60 million. On average, analysts forecast that MEI Pharma will post ($1.15) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at

About MEI Pharma

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Insider Buying and Selling by Quarter for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply